How do you ensure that a drug has an effect on the right protein – and nothing else? Chemist Anthe Janssen explored various methods for determining the selectivity of potential medicines. He also looked at the substance BIA 10-2474, after a man died in a French clinical trial in 2016. PhD defence on…

Laura Heitman has been awarded a VIDI grant for her innovative drug research. Heitman strives to optimize a drug’s binding kinetics at its target in order to ultimately fight diseases effectively. She even pleads for a paradigm shift in drug discovery.

Potential drugs that seem promising in the lab, but don’t show any activity in a person: they cost the industry an incredible amount of time and money. That’s why Indira Nederpelt focuses on a more efficient search for new drugs in her PhD, by determining the kinetics of a potential drug earlier on…

A team of five PhD students from Leiden University is in the running for first prize in the Pharmacometrics Skills Competition. In a drug development simulation, they apply their mathematical pharmacological skills to solve clinical problems. On 24 March they will compete in the finals in Orlando, F…

In the Phenomix Medical Delta Field Lab, which was officially opened on Thursday 9 July, scientists, healthcare institutions and businesses work together to develop innovative applications in the field of metabolomics. This research field makes it possible to determine which drugs will be effective…

Cancer is one of the main causes of death in the Netherlands. Leiden researchers are working to improve the treatment of different types of cancer in order to increase the patient’s quality of life. A better understanding of how cancer develops will make it possible to deliver personalised and precise…

Leiden chemists have developed a new technique with which they can determine the role of kinases – a group of proteins – in a living cell. This technique makes it easier to find new drug targets for diseases such as cancer and rheumatoid arthritis. The team published the findings in the journal Nature…

In April, the X-omics initiative was granted 17 million euros from the Dutch Organization for Scientific Research. The subsidy is part of the National Roadmap for large-scale scientific infrastructure, intended to build or renew large-scale research facilities. What new insights will this investment…

Medicines are becoming increasingly precise and innovative, but at the same time increasingly expensive. With their innovations, it is up to universities to increase competition, thus causing prices to drop. This is what newly appointed Professor of Biomolecular Analysis Hubertus Irth argues. His inaugural…

The coronavirus has the world in its grip. Finding a cure has never been more important. Unfortunately, the development of new drugs for treatment of the COVID-19 disease caused by the virus and development of a vaccine are complex, lengthy, and above all costly processes. With the help of computer…

In the search for new medicines against diseases such as cancer, a Leiden team has developed a new workflow. This approach combines artificial intelligence (AI) with molecular modelling and is suitable for finding unknown and innovative drug structures, the researchers proved.

Do you recall all those drugs that were hastily proposed as potential treatments for COVID-19? In the event of a future pandemic, the goal is to offer an effective treatment more quickly and efficiently. To achieve this, a team led by Coen van Hasselt is developing a platform that can speed up the process…

'It gave our team a big boost to hear that our work was valuable,' says medical chemist Elmer Maurits about the moment they won the Venture Challenge. With their company Iprotics, they want to develop a drug that can better treat patients with autoimmune diseases and blood cancers. 25,000 euros of prize…

Leiden biotech startup Azafaros has successfully completed a funding round, raising 25 million euros of investments for developing treatments of rare metabolic disorders. The company holds exclusive license to a library of novel patented compounds discovered by experts from Leiden University.

Finding structure in disordered proteins and developing drugs for undruggable diseases: it might sound like mission impossible, but pharmacologist Alireza Mashaghi and his team are right on top of it. Their project was awarded by NWO through the Open Competition Domain Science -XS, a competition that…

A consortium of research groups, including that of LACDR professor Erik Danen, will use an NWO Perspective grant of nearly five million euros to build a universal standard for organ-on-chip models. They aim to stimulate the application of these chips in the biomedical and pharmaceutical industry. Danen…

RARE-NL, a new collaboration between university hospitals, hopes to find treatments for rare diseases. Professor Teun van Gelder is representing the LUMC in the initiative.

Comparing individual health data with group data allows doctors to give personalised advice and patients to learn from one another's experiences. Wessel Kraaij, Professor of Applied Data Analytics, shows how personal data can have a valuable predictive function. Inaugural lecture 24 February.

Laura Heitman of the Leiden Academic Center for Drug Research (LACDR) has been nominated for the Prix Galien Research Award. This important pharmaceutical prize honors young, prominent researchers whose scientific research is of great importance for fundamental or clinical drug research.

Gerard van Westen and his group, together with pharmaceutical company Galapagos, start on developing software that invents new effective molecules. They will receive an NWO LIFT grant of 280,000 euros, of which 63,000 euros will come from Galapagos. The company will also bring its expertise in biology,…

Not taking into account the saturation of drug targets can lead to wrong conclusions about the duration of a drug's action. This is what former PhD candidate Wilbert de Witte writes together with the Leiden professors of pharmacology Meindert Danhof, Piet van der Graaf, and Liesbeth de Lange in Nature…

Leiden University, the LUMC and Janssen have signed a partnership agreement stating that they will collaborate in different areas, including infectious disease prevention, clinical tests, drug production and e-health. By joining forces, the three partners will be able to provide better, more innovative…

It is a stormy Sunday afternoon, with gusts of a whopping 110 kilometres per hour. Chemist Teun Sweere defies the enormous headwind on his city bike and wins the NK Headwind cycling after 22,5 minutes. A new highlight follows six months later: his PhD defence (14 June).

Erik Danen is looking at how to inhibit tumours that do not respond well to medicine – and he is making some headway. The Professor of Cancer Drug Target Discovery studies the interaction between tumour cells and their surroundings. Inaugural lecture on Friday 10 May.

Seven talented female scientists join the fight against cancer of the Oncode Insitute. Laura Heitman of the Leiden Academic Centre for Drug Research is one of the new Junior Investigators. ‘I hope to discover new druggable targets’.

What is the best method and time to test the effectiveness of medicines? PhD student Rob van Wijk of the Leiden Academic Centre for Drug Research (LACDR) discovered zebrafish larvae are best used in drug research when they are five days old. His findings were published on 15 February in the journal…

As of 1 November, Laura Heitman has been appointed full Professor of Molecular Pharmacology at the Leiden Academic Centre for Drug Research (LACDR). Heitman has been working on the understanding and improvement of drug-receptor interactions in early drug discovery. ‘My ultimate aim is to make medicines…